The company's proprietary silk-derived protein technology stabilizes vaccines, eliminating the need for refrigeration during storage and shipping. Additionally, Vaxess has created a novel sustained release microneedle for improved vaccine delivery. The company's therapies also provide long-term cancer immunity, clearance of distant tumors, and compatibility with antigens, improving patient outcomes with decreased treatment burdens. Vaxess is backed by venture capital and the Gates Foundation, and is committed to increasing access to life-saving products worldwide. Visit www.vaxess.com for more information.